Vesalius Biocapital wraps up third fund
Luxembourg-based Vesalius Biocapital, a life sciences venture firm, has closed its third fund at 120 million euros. The fund's investors includes the European Investment Fund. Vesalius Biocapital III targets later-stage European life science companies in drug development, medtech, diagnostics and digital health.
25 June 2019•3 mins read
